Active substance
Results for the substance vemurafenib
1 result
About this active substance
Vemurafenib is a medication used for the treatment of metastatic or unresectable melanoma with the BRAF V600E mutation. It is a selective inhibitor of the BRAF kinase, a protein involved in the MAPK/ERK signaling pathway, which plays a critical role in tumor cell growth and survival. By blocking the activity of mutated BRAF, vemurafenib slows tumor progression and can reduce tumor size.
The medication is administered orally, usually twice daily, and treatment requires regular monitoring to assess the patient's response and manage potential side effects.
Common side effects include skin rashes, photosensitivity, nausea, arthralgia, and fatigue. In rare cases, severe adverse reactions such as cutaneous squamous cell carcinoma, hepatotoxicity, or allergic reactions may occur.
Vemurafenib represents an important therapeutic option for patients with advanced melanoma, offering a chance to control disease progression and improve their quality of life.
The medication is administered orally, usually twice daily, and treatment requires regular monitoring to assess the patient's response and manage potential side effects.
Common side effects include skin rashes, photosensitivity, nausea, arthralgia, and fatigue. In rare cases, severe adverse reactions such as cutaneous squamous cell carcinoma, hepatotoxicity, or allergic reactions may occur.
Vemurafenib represents an important therapeutic option for patients with advanced melanoma, offering a chance to control disease progression and improve their quality of life.